Replies to post #169549 on Biotech Values

[iwfal]

ARQL -

There is difference in exposure between capsule form used in P2 and tablet form now being used in P3. ... ARQL believes that the exposure of 120mg tablet dose now being used in P3 HCC is similar to range seen in 240mg capsule dose that was used in P2 HCC trial.

While I think caravon is a little too negative (-g-) about the management, that oopsie is pretty bush league and lends support to caravon's view.